Mary Wilson
Well-known member
J Mol Biol. 2023 Aug 1; 435(15): 168173.
Published online 2023 Jun 8.
doi: 10.1016/j.jmb.2023.168173
Beatriz Perdiguero,[SUP]1,[/SUP][SUP]2,[/SUP][SUP]⁎[/SUP][SUP]†[/SUP] Patricia Pérez,[SUP]1,[/SUP][SUP]2,[/SUP][SUP]⁎[/SUP][SUP]†[/SUP] Laura Marcos-Villar,[SUP]1[/SUP] Guillermo Albericio,[SUP]1[/SUP]David Astorgano,[SUP]1[/SUP] Enrique Álvarez,[SUP]1,[/SUP][SUP]2[/SUP] Laura Sin,[SUP]1,[/SUP][SUP]2[/SUP] Carmen Elena Gómez,[SUP]1,[/SUP][SUP]2[/SUP]Juan García-Arriaza,[SUP]1,[/SUP][SUP]2[/SUP] and Mariano Esteban[SUP]1,⁎[/SUP]
Abstract
Although one member of the poxvirus family, variola virus, has caused one of the most devastating human infections worldwide, smallpox, the knowledge gained over the last 30 years on the molecular, virological and immunological mechanisms of these viruses has allowed the use of members of this family as vectors for the generation of recombinant vaccines against numerous pathogens. In this review, we cover different aspects of the history and biology of poxviruses with emphasis on their application as vaccines, from first- to fourth-generation, against smallpox, monkeypox, emerging viral diseases highlighted by the World Health Organization (COVID-19, Crimean-Congo haemorrhagic fever, Ebola and Marburg virus diseases, Lassa fever, Middle East respiratory syndrome and severe acute respiratory syndrome, Nipah and other henipaviral diseases, Rift Valley fever and Zika), as well as against one of the most concerning prevalent virus, the Human Immunodeficiency Virus, the causative agent of Acquired Immunodeficiency Syndrome. We discuss the implications in human health of the 2022 monkeypox epidemic affecting many countries, and the rapid prophylactic and therapeutic measures adopted to control virus dissemination within the human population. We also describe the preclinical and clinical evaluation of the Modified Vaccinia virus Ankara and New York vaccinia virus poxviral strains expressing heterologous antigens from the viral diseases listed above. Finally, we report different approaches to improve the immunogenicity and efficacy of poxvirus-based vaccine candidates, such as deletion of immunomodulatory genes, insertion of host-range genes and enhanced transcription of foreign genes through modified viral promoters. Some future prospects are also highlighted.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249371/
Published online 2023 Jun 8.
doi: 10.1016/j.jmb.2023.168173
Beatriz Perdiguero,[SUP]1,[/SUP][SUP]2,[/SUP][SUP]⁎[/SUP][SUP]†[/SUP] Patricia Pérez,[SUP]1,[/SUP][SUP]2,[/SUP][SUP]⁎[/SUP][SUP]†[/SUP] Laura Marcos-Villar,[SUP]1[/SUP] Guillermo Albericio,[SUP]1[/SUP]David Astorgano,[SUP]1[/SUP] Enrique Álvarez,[SUP]1,[/SUP][SUP]2[/SUP] Laura Sin,[SUP]1,[/SUP][SUP]2[/SUP] Carmen Elena Gómez,[SUP]1,[/SUP][SUP]2[/SUP]Juan García-Arriaza,[SUP]1,[/SUP][SUP]2[/SUP] and Mariano Esteban[SUP]1,⁎[/SUP]
Abstract
Although one member of the poxvirus family, variola virus, has caused one of the most devastating human infections worldwide, smallpox, the knowledge gained over the last 30 years on the molecular, virological and immunological mechanisms of these viruses has allowed the use of members of this family as vectors for the generation of recombinant vaccines against numerous pathogens. In this review, we cover different aspects of the history and biology of poxviruses with emphasis on their application as vaccines, from first- to fourth-generation, against smallpox, monkeypox, emerging viral diseases highlighted by the World Health Organization (COVID-19, Crimean-Congo haemorrhagic fever, Ebola and Marburg virus diseases, Lassa fever, Middle East respiratory syndrome and severe acute respiratory syndrome, Nipah and other henipaviral diseases, Rift Valley fever and Zika), as well as against one of the most concerning prevalent virus, the Human Immunodeficiency Virus, the causative agent of Acquired Immunodeficiency Syndrome. We discuss the implications in human health of the 2022 monkeypox epidemic affecting many countries, and the rapid prophylactic and therapeutic measures adopted to control virus dissemination within the human population. We also describe the preclinical and clinical evaluation of the Modified Vaccinia virus Ankara and New York vaccinia virus poxviral strains expressing heterologous antigens from the viral diseases listed above. Finally, we report different approaches to improve the immunogenicity and efficacy of poxvirus-based vaccine candidates, such as deletion of immunomodulatory genes, insertion of host-range genes and enhanced transcription of foreign genes through modified viral promoters. Some future prospects are also highlighted.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249371/